Introduction {#S1}
============

The immune system has evolved to fight infections. Upon exposure to microbial infections, the innate immune cells swiftly come to the body's defense, and, as infections get established, cells of the adaptive immune system respond to prevent future recurrences. Nevertheless, the immune system is not expected to recognize self-tissues as foreign. Should such misdirected responses occur, the autoimmunity that ensues needs to be distinguished from auto inflammatory diseases. However, both are marked by dysregulated and chronic activation of the immune system against self-antigens in the genetically predisposed individuals.

Autoimmunity can occur in any healthy individuals as evidenced by the detection of low levels of autoantibodies ([@B101]; [@B72]). Thus, autoimmunity and autoimmune disease should be distinguished clinically in that autoimmune disease occurs only when autoimmunity leads to tissue damage disrupting the functions of affected organs. The National Institutes of Health estimates that approximately 23 million people (up to 8% of the total population) could be affected by some form of approximately 80 known autoimmune diseases ([@B97]). In fact, autoimmune disease represents the fourth largest cause of disability among women in the United States, and is the eighth leading cause of death in women between the ages of 15 and 64 ([@B45]; [@B11]). Additionally, diagnosis of autoimmune diseases may take up to 5 years, and as many as five doctors may see a patient before proper diagnosis is made ([@B26]). Economically, annual direct health care costs resulting from autoimmune diseases are estimated to be \$100 billion (2005). Mechanistically, autoimmune diseases are considered to be disorders of the adaptive immune system. While autoantibodies mediate tissue damage via activation of complement proteins and leukocytes, autoreactive T cells induce damage via delayed-type hypersensitivity (DTH) reaction by secreting primarily T helper (Th)1, (interferon-γ) and Th17 (interleukin-17 family) cytokines. Two major factors have been implicated in the development of autoimmune responses: genetic susceptibility and environmental triggers such as exposure to microbes. Hypothetically, if ∼8% of the U.S. population are affected with some form of autoimmune disease, then it is hard to envision a scenario in which genetic defects exist in all of those affected. Thus, both genetic and environmental factors appear to be inseparable for occurrence of organ-specific autoimmune diseases that also include diseases of the cardiovascular system.

Conversely, auto inflammatory diseases involve direct participation of cells of the innate immune system, importantly neutrophils and macrophages. Cells of the adaptive immune system including major histocompatibility complex (MHC) alleles as well as infectious agents are excluded as the causative factors of auto inflammatory diseases ([@B78]). These disorders could be monogenetic (involvement of a single gene) ([@B39]) or polygenetic (involvement of more than one gene) ([@B38]). For example, mutations in inflammasome-related proteins, particularly NOD-like receptor (NLR) genes, are commonly implicated in auto inflammatory disorders with a phenotype of recurrent inflammation and periodic fever attacks ([@B103]). Nevertheless, auto inflammatory diseases can affect the cardiovascular system with a phenotype of myocarditis, pericarditis/inflammatory recurrent acute pericarditis (IRAP), as might occur in sarcoidosis and eosinophilic granulomatosis associated polyangiitis ([@B36]; [@B16]).

In this review, we discuss the mechanistic insights into the development of inflammatory heart disease (IHD), a group of disorders that affect different layers of the heart ([Figure 1](#F1){ref-type="fig"}). These include pericarditis (inflammation of the outer membranous sac), myocarditis (inflammation of the heart muscle), and endocarditis (inflammation of the inner lining of the heart and heart valves and/or coronary arteries) ([@B46]; [@B73]).

![Proposed mechanisms of inflammatory heart disease. All three layers (pericardium, myocardium, and endocardium) individually or together can be affected by various infectious and non-infectious causes. A variety of innate immune cells like neutrophils, macrophages, dendritic cells including γδ T cells, ILCs, and NK-T cells can infiltrate and take part in tissue destruction. The inflammatory damage can also lead to the release of cardiac antigens such as cardiac myosin, actin, cTnI, ANT, BAR, BCKD, SERCA2a, laminin, muscarinic receptor (MR), and heat shock proteins (HSP). The newly released antigens can trigger autoimmune responses by activating T cells and B cells in the draining lymph nodes, which can in turn infiltrate the heart and aggravate inflammation. It is also possible that the dying cardiac myocytes can be engulfed by macrophages as a part of the cleaning process by phagocytosis, and possibly, autophagy, and trigger pathogenic autoimmune responses in genetically susceptible individuals. Alternatively, misfolded or mutated or modified self-proteins as might occur with mitochondrial proteins can be seen by the immune system as foreign, resulting in pathological autoimmune responses. It also is possible that some of the intracellular proteins like HSPs may bear sequences similar to microbial HSPs leading to the generation of cross-reactive immune responses. In all these scenarios, self-antigens can be presented to both CD4 and CD8 T cells, and B cells. They mediate inflammation through, respectively, DTH, cytolysis and complement activation. However, it is to be noted that several putative cardiac antigens can be promiscuously expressed in non-cardiac tissues such as brain, lungs, liver, pancreas, kidney, and skeletal muscle, raising the question whether autoreactive responses generated in response to cardiac damage can also inflict damage in other organs.](fcell-08-00192-g001){#F1}

Pericarditis {#S1.SS1}
------------

The pericardium is made up of an outer single-layered fibrous membranous sac, and an inner double-layered serous sac that covers the heart and great blood vessels. Pericarditis, although self-limiting, can be complicated by pericardial effusion or pericardial constriction ([@B100]). While, 40--85% of patients affected with pericarditis may have unknown etiologies, recurrences can occur in up to 20--50% of those affected ([@B20]; [@B49]). Acute pericarditis can be seen in all age groups, but males are more commonly affected than females in the age group of 20--50 years ([@B6]). Estimates indicate that 0.1% of people admitted to hospitals with chest pain can have pericarditis ([@B62]). Similarly, 5% of those admitted with chest pain in emergencies unrelated to myocardial infarction might have pericarditis ([@B61]; [@B70]). The disease is self-limiting in most patients (70--90%) and respond well to anti-inflammatory medications like aspirin or non-steroidal anti-inflammatory drugs with colchicine, corticosteroids, and anakinra (IL-1 receptor antagonist) ([@B61]). A variety of infectious and non-infectious triggers have been implicated in the causation of pericarditis ([Table 1](#T1){ref-type="table"}). Microbes frequently associated with pericarditis include bacteria \[*Staphylococcus aureus*, *Streptococcus*, *Haemophilus*, *Coxiella burnetti*, and *Mycobacterium tuberculosis* (M. tb)\] ([@B86]; [@B20]), viruses \[Echovirus, Coxsackievirus B (CVB), parvovirus B19, human herpes virus 6 (HHV6), Epstein-Barr Virus (EBV), human immunodeficiency virus (HIV), and influenza B virus (IBV)\] ([@B20]). The disease can also arise from co-infections caused by multiple organisms such as *S. aureus* and M. tb in immune-suppressive individuals as might occur in HIV infection imposing a clinical challenge to target specific pathogens for therapy particularly in patients with recurrences ([@B67]).

###### 

Potential major causes of inflammatory heart disease.

                 **Microbes**                             **Non-microbes**
  -------------- ---------------------------------------- -----------------------------------
  Pericarditis   **Viruses**                              Systemic lupus erythematosus
                 Enteroviruses (CVB and echovirus)        Sjögrens syndrome
                 Herpesviruses (EBV and HHV6)             Rheumatoid arthritis
                 Adenovirus                               Scleroderma
                 Parvovirus B19                           Familial Mediterranean fever
                 Influenza virus                          TNFR-associated periodic syndrome
                 Hepatitis B and C viruses                Neoplasms
                 Human immunodeficiency virus             
                 **Bacteria**                             
                 *Mycobacterium tuberculosis*             
  Myocarditis    **Viruses**                              
                 Enteroviruses (CVB and echovirus)        Inflammatory bowel disease
                 Erythroviruses (Parvovirus B19)          Giant cell myocarditis
                 Adenovirus                               Diabetes mellitus
                 Human herpesvirus 6 and 7                Sarcoidosis
                 Hepatitis C virus                        Systemic lupus erythematosus
                 Human immunodeficiency virus             Thyrotoxicosis
                 Epstein-Barr virus                       Alcohol
                 Cytomegalovirus                          Doxorubicin
                 Influenza virus                          [*Hypersensitivity*]{.ul}
                 **Bacteria**                             Sulphonamides
                 *Corynebacterium diphtheriae*            Penicillins
                 *Staphylococcus aureus*                  Digoxin
                 *Streptococcus aureus*                   
                 *Borrelia burgdorferi*                   
                 *Mycoplasma pneumoniae*                  
                 *Treponema pallidum*                     
                 **Fungus**                               
                 *Aspergillus* species                    
                 *Candida* species                        
                 *Coccidioides* species                   
                 *Cryptococcus* species                   
                 *Histoplasma* species                    
                 **Protozoa**                             
                 *Trypanosoma cruzi*                      
                 *Babesia* species                        
  Endocarditis   **Bacteria**                             Intravenous drug usage
                 *Staphylococcus aureus*                  Rheumatoid arthritis
                 *Streptococci* species                   Systemic lupus erythematosus
                 *Enterococci* species                    Diabetes mellitus
                 *Haemophilus* species                    Cancer
                 *Aggregatibacter* species                Poor dental health care
                 *Cardiobacterium* species                
                 *Actinobacillus actinomycetemcomitans*   
                 *Eikenella corradens*                    
                 *Kingella* species                       
                 **Fungus**                               
                 *Candida* species                        

CVB, Coxsackie B virus; EBV, Epstein-Barr virus; HHV6, human herpesvirus 6; TNFR, tumor necrosis factor receptor.

The most alarming complication of acute pericarditis is IRAP, which occurs in 15--30% of patients due to auto inflammatory or autoimmune events ([@B69]). Auto inflammatory reactions in IRAP can result from virus infections such as Echovirus, CVB, and bacteria like M. tb, but the affected individuals should be negative for microbe-specific RNA and antibodies (IgM) to qualify for IRAP-diagnosis ([@B61]; [@B17]; [@B70]). However, the IRAP patients can carry anti-heart (AHA: myosin heavy chain β and β and myosin light chain-1v isoform) and anti-intercalated-disk autoantibodies, in addition to non-cardiac autoantibodies ([@B76]; [@B68]). Impaired function of the innate immune system resulting in auto inflammatory pericarditis can occur due to mutations in immune response genes. Two such examples include mutations in *MEFV* and *TNFRSF1A* that cause Mediterranean fever and TNF receptor-associated periodic syndrome, respectively ([@B25]; [@B75]).

As for autoimmune pericarditis, involvement of the pericardium has been reported in systemic autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), progressive systemic sclerosis, Sjögrens syndrome, and polyarthritis, but the affected patients can remain asymptomatic ([@B24]). Pericardial fluid, and not plasma samples, may contain inflammatory mediators like IL-6, IL-8, and IFN-γ with a preferential detection of anti-myolemma over anti-sarcolemma antibodies, implying that local autoimmune events can occur specific to the heart ([@B87]). Recent reports indicate that serum carcinoembryonic antigen cell adhesion molecule 1 and MHC class I chain-related protein A can be used as biomarkers and prognostic markers in pericarditis patients, respectively, whereas the appearance of cardiac troponin-T (cTnT) signifies occurrence of acute and recurrent pericarditis ([@B58]; [@B54]).

Myocarditis {#S1.SS2}
-----------

Myocarditis may involve cardiac myocytes, interstitial, or vascular elements of the heart that can be manifested as perimyocarditis involving the pericardium. Affected patients may show clinical manifestations of disease or may remain asymptomatic, but histopathologic changes can be detected in those affected ([@B42]). Myocarditic hearts can contain variable numbers of lymphocytes and macrophages, but antibody-mediated injury also can be expected ([@B29]; [@B96]). The disease is generally regarded as an underdiagnosed cause of acute heart failure, and sudden death or dilated cardiomyopathy (DCM) can be expected in young adults ([@B40]). The annual global prevalence of myocarditis has been estimated to be ∼22 cases per 100,000 patients ([@B40]; [@B94]), and 1--5% of acute viral infections may have myocardial involvement ([@B46]). Furthermore, myocarditis is relatively more common in young men than their female counterparts, indicating that sex hormones can influence the disease outcome ([@B66]). While virus-induced myocarditis in neonates and children may lead to fulminant myocarditis, lymphocytic or giant cell myocarditis is generally noted in the median age group of 42--43 years ([@B92]). Approximately 10--20% of those affected with acute myocarditis as young adults develop chronic myocarditis, DCM, and congestive heart failure. Approximately half of these patients undergo heart transplantation due to the lack of effective treatment options ([@B22]; [@B92]).

Myocarditis can occur in association with a wide spectrum of infectious agents, systemic diseases, and hypersensitivity to drugs and toxins ([Table 1](#T1){ref-type="table"}). While viral infections caused by enteroviruses like CVB, adenoviruses, parvovirus B19, CMV, EBV, HIV, hepatitis C virus, and influenza virus are commonly suspected as causes of myocarditis in the developed world ([@B88]), rheumatic carditis/diphtheria caused by *Streptococcus aureus* and Chagas disease caused by *Trypanosoma cruzi* are implicated in developing countries ([@B4]; [@B57]; [@B5]; [@B85]; [@B18]). More recently, it has been noted that patients receiving checkpoint inhibitors for tumors can develop autoimmune myocarditis, raising the question whether anti-tumor T cells may recognize cardiac antigens by cross-reactivity with microbial antigens ([@B21]; [@B77]). In support of this proposition, it was recently shown translationally that commensal bacteria can promote inflammatory cardiomyopathy by elevating *Bacteroides-*specific CD4 T cell and B cell responses in human myocarditis patients ([@B56]). This observation was also complemented in the mouse model, where cardiac myosin-specific Th17 cells could be activated by cross-reactive mimic peptides from *Bacteroides thetaiotaomicron*. These findings suggest that the microbiome could predispose genetically susceptible individuals undergoing checkpoint inhibitors to develop myocarditis, leading to the suggestion that they can potentially be treated with antibiotics ([@B56]).

In North America, myocarditis/DCM has been frequently associated with enterovirus infections like CVB, and approximately 50% of DCM patients can carry CVB-reactive antibodies, and viral RNA can be detected in 70% of them ([@B9]; [@B52]). However, other viruses namely, parvovirus B19 and HHV-6 are now being increasingly reported in association with myocarditis/DCM ([@B3]; [@B88]). The CVB infection is generally used to understand how viral infections can trigger autoimmune responses. CVB pathogenesis involves both virus-induced (direct) and host-induced (indirect) mechanisms ([@B28]). Because it is a cardiotropic and lytic virus, CVB can directly lyse cardiomyocytes during viral replication. Experimentally, CVB infection in mice can have two phases in continuum: acute myocarditis (viral) up to day 14--18 and chronic myocarditis (non-viral) beyond 18 days ([@B93]). During the initial stages of CVB infection, activation of innate immune cells results in the production of the pro-inflammatory cytokines IL-1, IL-6, TNF-β, soluble IL-1R-like 1 also called, sST2 and IFNs ([@B48]; [@B84]). Such proteins can potentially be used as markers of myocarditis. For example, it has been recently shown that men with myocarditis had higher levels of sST2 than women. This finding was later confirmed experimentally, where gonadectomy with testosterone, but not estradiol replacement, led to increased levels of sST2 in male mice with myocarditis ([@B30]). These data also add credence to the relevance of experimental models to human diseases. As to adaptive immune response, Th cells appear to play a decisive role in the induction of chronic myocarditis/DCM, but involve complex mechanisms. While, the Th1 cells can protect acute myocarditis and prevent viral replication ([@B43]; [@B44]), Th2 cells, although they have the ability to attenuate acute myocarditis via anti-inflammatory cytokines and Treg cells ([@B51]; [@B71]), can induce acute cardiac remodeling leading to chronic myocarditis/DCM ([@B1]). Conversely, Th17 cells contribute to the development of both acute myocarditis (but without affecting viral replication), as well as cardiac remodeling/DCM events and heart failure ([@B47]) suggesting that the disease course of viral myocarditis may be dictated by nature and the amount of Th cytokines being produced. Nonetheless, these findings raise a question as to the mechanisms of generation of pathogenic cardiac-reactive T cells, should they be antigen-specific.

One mechanism is molecular mimicry, which involves the generation of cross-reactive immune responses against self-antigens. In fact, sequence similarities of up to 40% have been detected between CVB viral protein~1~ (VP~1~), streptococcal M protein, and cardiac myosin; synthetic peptides containing these sequences block monoclonal antibody (mAb) reactivity to streptococcal M protein ([@B33]). Furthermore, murine anti-streptococcal mAbs that cross-react with streptococcal M protein and human cardiac myosin were found to neutralize CVB viruses (CVB3 and CVB4) and poliovirus type 1 ([@B33]). Additionally, T lymphocytes from CVB-infected animals can respond to peptides from streptococcal M protein ([@B59]). Similarly, the N-terminal region four peptide from streptococcus could induce IHD in MRL/++ mice, whereas induction of anergy to this peptide protects mice from developing CVB-induced myocarditis ([@B60]).

Another mechanism is epitope spreading which may occur as a result of release of self-antigens primarily by viral damage, leading to induction of autoimmunity secondarily ([@B52]). In addressing this phenomenon, we had demonstrated that A/J mice infected with CVB produce Myhc-α 334-352-specific CD4 T cell responses that are pathogenic in nature ([@B55]). Using MHC class II dextramers specific to Myhc 334--352, we showed that Myhc-specific, CD4 T cells can infiltrate into the hearts of animals infected with CVB during the post infectious phase of CVB infection ([@B55]). By expanding this observation, we may be able to determine whether autoreactive T cells specific to multiple cardiac antigens could contribute to CVB pathogenesis. This effort, however, requires identification of myocarditogenic epitopes for other putative cardiac antigens implicated in myocarditis/DCM patients ([Figure 1](#F1){ref-type="fig"}).

Endocarditis {#S1.SS3}
------------

Endocarditis can also be caused by infective or non-infective agents ([Table 1](#T1){ref-type="table"}), that have a male preponderance ([@B2]). Incidence of infective endocarditis in developed countries is 3--10 cases per 100,000 people, and the disease prevalence is expected to be high in developing countries ([@B41]; [@B98]). Endocarditic lesions, primarily called vegetation, consist of microorganisms, inflammatory cells, platelets, and fibrin. Microbes such as *S. aureus*, *Streptococcus* species, *Enterococcus* species, and HACEK Gram-negative bacteria (*Haemophilus* species, *Actinobacillus actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens* and *Kingella* species) account for more than 90% of endocarditis cases that may have a nosocomial or odontogenic origin ([Table 1](#T1){ref-type="table"}; [@B82]; [@B90]; [@B7]; [@B98]). However, highest mortalities occur with *S. aureus* and the non-HACEK group pathogens such as *Candida albicans* ([@B7]). Additionally, infective endocarditis also can occur in intravenous drug abusers or in association with HIV infection, diabetes mellitus, rheumatoid arthritis, Sjögrens syndrome and cancer ([@B79]; [@B50]; [@B99]; [@B102]; [@B95]; [Table 1](#T1){ref-type="table"}). These observations suggest that multiple pathomechanisms may contribute to the development of endocarditis.

Damage to the endocardium can result from valve sclerosis, rheumatic valvulitis, or direct colonization/vegetation by bacteria like *S. aureus* and *Streptococcus* species ([@B23]). The main sequelae of endocarditis include damage to the heart valve and endothelial scarring, leading to congestive heart failure as might occur in autoimmune rheumatic diseases. Endocarditis resulting from *Streptococcus* species., has been used as a prototypic disease model to address how cross-reactive autoimmune responses can lead to heart dysfunction ([@B65]; [@B32]). It has been shown that mAbs specific to Streptococcus M protein or the group A streptococcal epitope *N*-acetyl-β[D]{.smallcaps}-glucosamine can cross-react with cardiac myosin and laminin ([@B65]; [@B53]). The finding that anti-streptococcal antibodies cross-react with human and canine cardiac sarcolemma proteins but not kidney or skeletal muscle, suggests that sarcoplasmic antigens can be targeted in autoimmune endocarditis ([@B35]; [@B32]).

Animal models have been developed to study the immune pathology of endocarditis and valvular inflammation. Intraperitoneal injection of cell lysate from group A streptococci into Swiss Webster mice results in aortic and mitral valve stenosis, chronic inflammation, and scarring that mimic human chronic rheumatic carditis ([@B31]; [@B34]). In the Lewis rat model, immunization with streptococcal M protein leads to the induction of cross-reactive T cells that are pathogenic in nature ([@B89]). Similarly, Lewis rats immunized with M protein can develop valvulitis in mitral valves, but with minimal myocardial involvement ([@B89]). Expectedly, lymph node cells obtained from immunized animals respond to human cardiac myosin, but not human and rabbit skeletal myosin and actin, although both human cardiac and skeletal myosin share extensive sequence identity ([@B89]). However, it is interesting that, in spite of protein sequence identity between streptococcal M proteins and cardiac myosin, myocardial involvement was noted to be minimal relative to valvulitis in the immunized Lewis rats. Likewise, laminin present in the valves has been shown to cross-react with both anti-streptococcal and myosin antibodies, and cross-reactive T cells generated by immunization with laminin can induce valvulitis without significant involvement of the myocardium ([@B89]).

Endocarditis can be seen in patients with RA, SLE, and rheumatic fever, in which both joint and cardiovascular systems could be affected. RA patients can also carry cardiac-specific antibodies ([@B19]). To study the immune-pathogenic mechanism of inflammatory arthritis, the K/BxN TCR transgenic mouse model has been developed ([@B81]). The transgenic mice express TCR specific to glucose-6-phosphate isomerase (GPI), which plays a key role in catalyzing the interconversion of glucose-6-phosphate to fructose-6-phosphate ([@B27]). GPI-primed B cells produce autoantibodies that can induce arthritis ([@B80]). Recent studies suggest that transgenic mice can develop both arthritis and endocarditis, but through two independent pathways. While complement C5 protein is critical for development of arthritis, but not endocarditis, occurrence of endocarditis, but not arthritis, requires the participation of FcRγ ([@B12]). Adoptive transfer of serum from transgenic mice into naïve animals led to the development of arthritis that was devoid of endocarditis, implying that arthritis is an antibody-mediated disease ([@B74]). Conversely, animals depleted of CD4^+^ T cells fail to develop endocarditis, but arthritis remains unaffected, suggesting that T cells play a critical role in the development of endocarditis ([@B12]). Such disease models may be helpful in studying the immune mechanisms of rheumatic diseases that involve both synovial joints and/or the endocardium.

Discussion {#S2}
==========

As described above, etiologically, IHD can be triggered by a wide range of microbes, therefore posing a clinical challenge, that necessitates identification of triggers to initiate pathogen-specific therapies. Such avenues are clinically complicated, since affected patients can have co-infections caused by microbes belonging to different classes. For example, HIV patients can develop pericarditis in association with *S. aureus* and M. tb infections ([@B67]). Similarly, myocarditis can result from co-infection with HHV-6 and parvovirus B19 ([@B91]). Likewise, some infections like EBV and parvovirus B19, may occur as a result of their reactivation, respectively, in CVB3 and hepatitis virus, and HHV-6 infections ([@B14]; [@B8]). Such scenarios are likely because up to 95% of the United States population is affected with EBV infection ([@B8]). Furthermore, tissue destruction may not necessarily result directly from cardiotropic pathogens like CVB3 and adenovirus. For example, parvovirus B19 targeting endothelial cells can induce myocarditis via endothelial dysfunction and initiate inflammation ([@B15]).

Nevetheless, following infection-tiggered IHD, the immune system in immune-competent individuals is expected to repair the damaged tissue with or without successful clearance of primary offenders. But such an ability of the immune system to self-cure is relatively limited for cardiac cells, especially adult cardiac myocytes because of their limited regenerative capacity ([@B63]). This scenario can be complicated by the potential occurrence of secondary damage resulting from autoimmune responses in genetically susceptible individuals. In addressing this phenomenon, we have noted that CVB3 infection can lead to the generation of cardiac myosin-specific T cells that can contribute to post-infectious myocarditis in the absence of detectable virions in infected animals ([@B55]). Based on this observation, we envision that cardiac-reactive T cells specific for multiple autoantigens could be generated in infections caused by cardiotropic pathogens that may have implications in diagnosis and therapy of IHD.

Diagnostically, it is extremely challenging to identify the causative agents for IHD with certainty, especially if polymicrobes (co-infections) are involved. Additionally, one or more manifestions of IHD (pericarditis, myocarditis, or endocarditis) can potentially occur concurrently in affected patients. Nonetheless, it may be possible to develop diagnostic panels for commonly found pathogens like viruses and bacteria. These may include PCR-based molecular markers or antibody assays with the challenge that clinical specimens, especially endomycardial biopsies, need to be collected in a timely fashion to make a reliable diagnosis. This is especially important in chronically affected individuals with no overt clinical signs suggestive of known microbial infections. Such an approach, if supported by routinely used serum biomarkers namely, cardiac troponin I and T, creatinine kinase-MB, C-reactive protein, myoglobin, natriuetic peptides, and sST2 ([@B13]; [@B84]; [@B30]; [@B64]) may have diagnostic value. A limitation of this approach is that the offending agents would be gone by that time, except being suspects, which may not alter treatment approaches to be followed clinically.

Thus, the complex nature of IHD is therapeutically challenging in the medical management of affected individuals. Although, various clinical trials reported thus far have yielded mixed successes, two major approaches seem to be encouraging. These include immune therapies (administration of intravenous immunoglobulins or immunoglobulin adsorption), and anti-viral agents. The former approach appeared to be effective in patients with giant cell myocarditis and sarcoidosis who are negative for viruses ([@B88]). Conversely, this approach offered no advantage in those positive for viruses ([@B88]). The latter group of patients, however, can potentially be treated with anti-viral agents as reported in parvovirus B19 (peramivir) and influenza (acyclovir) infections, with or without immune suppressive therapy, respectively ([@B37]; [@B10]). Although such outcomes are rarely reported, the therapeutic value of anti-viral compounds can be validated only in large clinical trials that involve careful recruitment of patient populations and appropriate controls. Finally, as to autoimmunity, use of general immune suppressants potentially elimimate most naïve lymphocytes that can seriously impair a host's defense mechanisms against microbes. Thus, immune strategies are expected to target disease-inducing, autoreactive T cells or B cells by sparing naïve repertoires. To this end, various selective immune suppressants have been investigated that may hold promise in the future.
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AHA

:   anti-heart antibodies

ANT

:   adenine nucleotide translocator

BAR

:   beta adrenergic receptor

BCKD

:   branched chain ketoacid dehydrogenase

CMV

:   cytomegalovirus

cTnI

:   cardiac troponin I

cTnT

:   cardiac troponin T

CVB

:   Coxsackievirus B
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:   dilated cardiomyopathy
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:   glycosyl phosphatidyl inositol

HHV

:   human herpesvirus
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:   human immunodeficiency virus

HSPs

:   heat shock proteins

IBV

:   influenza B virus

IFN

:   interferon

IHD

:   inflammatory heart disease

IL

:   interleukin

ILCs

:   innate lymphoid cells

IRAP

:   inflammatory recurrent acute pericarditis

mAb
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MHC

:   major histocompatibility complex

M. tb

:   *Mycobacterium tuberculosis*
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:   natural killer-T cells
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:   NOD-like receptor
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:   polymerase chain reaction
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:   rheumatoid arthritis

SERCA2a

:   sarcoplasmic/endoplasmic reticulum Ca^2+^ ATPase 2a
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:   systemic lupus erythematosus
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:   T cell receptor
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:   T helper
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:   tumor necrosis factor.
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